NOR型非球面角膜塑形镜治疗中度近视疗效分析  

Analysis of the Effect of Aspheric Based Curve⁃designed NOR Ortho Keratography in Patients with Moderate Myopia

作　　者：薛维娜 张娟 闫茹 王娟 曹珂欣 XUE Weina;ZHANG Juan;YAN Ru;WANG Juan;CAO Kexin(The Second Hospital of WeiNan,Weinan 714000,China)

机构地区：[1]渭南市第二医院,渭南714000

出　　处：《玻璃搪瓷与眼镜》2024年第1期8-13,共6页Glass Enamel & Ophthalmic Optics

摘　　要：将中度近视患者按照基线期主观验光球镜度数分为A组(-3.00 D≤主观验光球镜度数≤-4.00 D)和B组(-4.00 D<主观验光球镜度数≤-5.00 D),分别检查患者基线期、戴镜1 d、1周、1个月和3个月后相应的眼科相关指标。结果显示,戴镜后各随访时间节点,2组患者裸眼远视力较基线期均显著提升(P<0.05)。戴镜1个月后,2组患者视力达到0.1 logMAR(小数视力0.8)的比例分别为88.9%和90.6%;戴镜3个月后,2组患者主观验光的球镜度、柱镜度、屈光度组间比较均无统计学差异(P>0.05),与基线期比较均显著降低(P<0.05),B组改变量均高于A组(P<0.05)。中度近视患者配戴NOR型非球面角膜塑形镜可有效提升患者裸眼远视力,降低屈光度,并且不影响眼压及角膜内皮细胞数量,镜片配适度高,并发症少,配合双氧护理液使用安全可靠。Patients with moderate myopia were divided into group A(-3.00 D≤subjective sphericity≤-4.00 D)and group B(-4.00 D<subjective sphericity≤-5.00 D)based on baseline subjective sphericity.Ophthalmic examinations of the baseline period,follow-up at 1 day,1 week,1 month and 3 months after wearing OK lens were done.The results showed that at each follow-up time point,the UDVA of both groups of patients significantly improved compared to the baseline period(P<0.05).At 1 month,the proportion of patients in both groups who achieved 0.1 logMAR(Decimal visual acuity 0.8)of UDVA was 88.9%and 90.6%,respectively;Three months after wearing OK lens,there was no statistically significant difference in the subjective refraction of spherical,cylinder,and diopter between the two groups of patients(P>0.05),and there was a significant decrease compared to the baseline period(P<0.05).The amount of change in group B was higher than that in group A(P<0.05).Wearing NOR aspherical OK lenses in patients with moderate myopia can effectively improve UCDVA,reduce refractive power,and do not affect intraocular pressure and corneal endothelial cells.The lens matching is really high,with fewer complications,and it is safe and reliable to use in conjunction with hydrogen peroxide care solution.

关 键 词：角膜塑形镜 中度近视 近视矫正 安全性 

分 类 号：R[医药卫生]